{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T16:06:09Z","timestamp":1777305969012,"version":"3.51.4"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T00:00:00Z","timestamp":1634860800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2022,2,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec>\n                <jats:title>Aims<\/jats:title>\n                <jats:p>To investigate the prognostic value of baseline imaging features for overall survival (OS) and liver decompensation (LD) in patients with hepatocellular carcinoma (HCC).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Design<\/jats:title>\n                <jats:p>Patients with advanced HCC from the SORAMIC trial were evaluated in this post hoc analysis. Several radiological imaging features were collected from baseline computed tomography (CT) and magnetic resonance imaging (MRI) imaging, besides clinical values. The prognostic value of these features for OS and LD (grade 2 bilirubin increase) was quantified with univariate Cox proportional hazard models and multivariate Least Absolute Shrinkage and Selection Operator (LASSO) regression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Three hundred and seventy-six patients were included in this study. The treatment arm was not correlated with OS. LASSO showed satellite lesions, atypical HCC, peritumoral arterial enhancement, larger tumour size, higher albumin\u2013bilirubin (ALBI) score, liver\u2013spleen ratio &lt;1.5, ascites, pleural effusion and higher bilirubin values were predictors of worse OS, and higher relative liver enhancement, smooth margin and capsule were associated with better OS. LASSO analysis for LD showed satellite lesions, peritumoral hypointensity in hepatobiliary phase, high ALBI score, higher bilirubin values and ascites were predictors of LD, while randomisation to sorafenib arm was associated with lower LD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Imaging features showing aggressive tumour biology and poor liver function, in addition to clinical parameters, can serve as imaging biomarkers for OS and LD in patients receiving sorafenib and selective internal radiation therapy for HCC.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41416-021-01577-6","type":"journal-article","created":{"date-parts":[[2021,10,22]],"date-time":"2021-10-22T15:04:30Z","timestamp":1634915070000},"page":"211-218","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Prognostic value of baseline imaging and clinical features in patients with advanced hepatocellular carcinoma"],"prefix":"10.1038","volume":"126","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5234-1921","authenticated-orcid":false,"given":"Osman","family":"\u00d6cal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0268-9078","authenticated-orcid":false,"given":"Michael","family":"Ingrisch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muzaffer Reha","family":"\u00dcm\u00fctl\u00fc","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bora","family":"Peynircioglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Loewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"van Delden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Vandecaveye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernhard","family":"Gebauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph J.","family":"Zech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Sengel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irene","family":"Bargellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Iezzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Benito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Pech","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Malfertheiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Ricke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2481-5410","authenticated-orcid":false,"given":"Max","family":"Seidensticker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,10,22]]},"reference":[{"key":"1577_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394\u2013424.","journal-title":"CA Cancer J Clin"},{"key":"1577_CR2","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","volume":"10","author":"V Mazzaferro","year":"2009","unstructured":"Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35\u201343.","journal-title":"Lancet Oncol"},{"key":"1577_CR3","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1056\/NEJMoa0708857","volume":"359","author":"JM Llovet","year":"2008","unstructured":"Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl J Med. 2008;359:378\u201390.","journal-title":"N. Engl J Med"},{"key":"1577_CR4","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S1470-2045(08)70285-7","volume":"10","author":"AL Cheng","year":"2009","unstructured":"Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25\u201334.","journal-title":"Lancet Oncol"},{"key":"1577_CR5","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1200\/JCO.2017.76.0892","volume":"36","author":"PKH Chow","year":"2018","unstructured":"Chow PKH, Gandhi M, Tan SB, Khin MW, Khasbazar A, Ong J, et al. SIRveNIB: selective internal radiation therapy versus sorafenib in Asia-Pacific patients with hepatocellular carcinoma. J Clin Oncol. 2018;36:1913\u201321.","journal-title":"J Clin Oncol"},{"key":"1577_CR6","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1016\/S1470-2045(17)30683-6","volume":"18","author":"V Vilgrain","year":"2017","unstructured":"Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624\u201336.","journal-title":"Lancet Oncol"},{"key":"1577_CR7","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.jhep.2019.08.006","volume":"71","author":"J Ricke","year":"2019","unstructured":"Ricke J, Kl\u00fcmpen HJ, Amthauer H, Bargellini I, Bartenstein P, de Toni EN, et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J Hepatol. 2019;71:1164\u201374.","journal-title":"J Hepatol"},{"key":"1577_CR8","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1016\/j.jhep.2016.07.020","volume":"65","author":"JA Marrero","year":"2016","unstructured":"Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, et al. Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: the GIDEON study. J Hepatol. 2016;65:1140\u20137.","journal-title":"J Hepatol"},{"key":"1577_CR9","doi-asserted-by":"publisher","first-page":"4315","DOI":"10.2217\/fon-2019-0658","volume":"16","author":"DH Palmer","year":"2020","unstructured":"Palmer DH, Hawkins NS, Vilgrain V, Pereira H, Chatellier G, Ross PJ. Tumor burden and liver function in HCC patient selection for selective internal radiation therapy: SARAH post-hoc study. Fut. Oncol. 2020;16:4315\u201325.","journal-title":"Fut. Oncol"},{"key":"1577_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-019-0264-y","volume":"19","author":"YH Chuang","year":"2019","unstructured":"Chuang YH, Ou HY, Yu CY, Chen CL, Weng CC, Tsang LL, et al. Diffusion-weighted imaging for identifying patients at high risk of tumor recurrence following liver transplantation. Cancer Imaging. 2019;19:74.","journal-title":"Cancer Imaging"},{"key":"1577_CR11","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jhep.2018.01.024","volume":"68","author":"AY Kim","year":"2018","unstructured":"Kim AY, Sinn DH, Jeong WK, Kim YK, Kang TW, Ha SY, et al. Hepatobiliary MRI as novel selection criteria in liver transplantation for hepatocellular carcinoma. J Hepatol. 2018;68:1144\u201352.","journal-title":"J Hepatol"},{"key":"1577_CR12","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/S0168-8278(02)00360-4","volume":"38","author":"H Imamura","year":"2003","unstructured":"Imamura H, Matsuyama Y, Tanaka E, Ohkubo T, Hasegawa K, Miyagawa S, et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol. 2003;38:200\u20137.","journal-title":"J Hepatol"},{"key":"1577_CR13","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1148\/radiol.13120775","volume":"267","author":"JW Choi","year":"2013","unstructured":"Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology. 2013;267:776\u201386.","journal-title":"Radiology"},{"key":"1577_CR14","doi-asserted-by":"crossref","unstructured":"Ricke J, Steffen IG, Bargellini I, Berg T, Jaureguizar JIB, Gebauer B, et al. Gadoxetic acid-based hepatobiliary MRI in hepatocellular carcinoma. JHEP Rep. 2020;100173.","DOI":"10.1016\/j.jhepr.2020.100173"},{"key":"1577_CR15","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1111\/liv.12751","volume":"35","author":"BK Kim","year":"2015","unstructured":"Kim BK, Kim KA, An C, Yoo EJ, Park JY, Kim DY, et al. Prognostic role of magnetic resonance imaging vs. computed tomography for hepatocellular carcinoma undergoing chemoembolization. Liver Int. 2015;35:1722\u201330.","journal-title":"Liver Int"},{"key":"1577_CR16","doi-asserted-by":"publisher","first-page":"2623","DOI":"10.1007\/s00330-009-1467-6","volume":"19","author":"U Motosugi","year":"2009","unstructured":"Motosugi U, Ichikawa T, Tominaga L, Sou H, Sano K, Ichikawa S, et al. Delay before the hepatocyte phase of Gd-EOB-DTPA-enhanced MR imaging: is it possible to shorten the examination time? Eur Radiol. 2009;19:2623\u20139.","journal-title":"Eur Radiol"},{"key":"1577_CR17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1002\/jmri.22876","volume":"35","author":"KA Kim","year":"2012","unstructured":"Kim KA, Kim MJ, Jeon HM, Kim KS, Choi JS, Ahn SH, et al. Prediction of microvascular invasion of hepatocellular carcinoma: usefulness of peritumoral hypointensity seen on gadoxetate disodium-enhanced hepatobiliary phase images. J Magn Reson Imaging. 2012;35:629\u201334.","journal-title":"J Magn Reson Imaging"},{"key":"1577_CR18","doi-asserted-by":"crossref","unstructured":"Simon N, Friedman JH, Hastie T, Tibshirani R. Regularization paths for Cox\u2019s proportional hazards model via coordinate descent. 2011;39:13.","DOI":"10.18637\/jss.v039.i05"},{"key":"1577_CR19","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.2967\/jnumed.120.242933","volume":"61","author":"M Venerito","year":"2020","unstructured":"Venerito M, Pech M, Canbay A, Donghia R, Guerra V, Chatellier G, et al. NEMESIS: Non-inferiority, Individual Patient Meta-analysis of Selective Internal Radiation Therapy with Yttrium-90 resin microspheres versus sorafenib in advanced hepatocellular carcinoma. J Nucl Med. 2020;61:1736\u201342.","journal-title":"J Nucl Med"},{"key":"1577_CR20","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1080\/0284186X.2020.1759826","volume":"59","author":"TA Labeur","year":"2020","unstructured":"Labeur TA, Hofsink Q, Takkenberg RB, van Delden OM, Math\u00f4t RAA, Schinner R, et al. The value of sorafenib trough levels in patients with advanced hepatocellular carcinoma - a substudy of the SORAMIC trial. Acta Oncol. 2020;59:1028\u201335.","journal-title":"Acta Oncol"},{"key":"1577_CR21","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.jhep.2017.04.024","volume":"67","author":"S Lee","year":"2017","unstructured":"Lee S, Kim SH, Lee JE, Sinn DH, Park CK. Preoperative gadoxetic acid-enhanced MRI for predicting microvascular invasion in patients with single hepatocellular carcinoma. J Hepatol. 2017;67:526\u201334.","journal-title":"J Hepatol"},{"key":"1577_CR22","doi-asserted-by":"publisher","first-page":"2539","DOI":"10.1245\/s10434-009-0453-1","volume":"16","author":"T Iguchi","year":"2009","unstructured":"Iguchi T, Aishima S, Sanefuji K, Fujita N, Sugimachi K, Gion T, et al. Both fibrous capsule formation and extracapsular penetration are powerful predictors of poor survival in human hepatocellular carcinoma: a histological assessment of 365 patients in Japan. Ann Surg Oncol. 2009;16:2539\u201346.","journal-title":"Ann Surg Oncol"},{"key":"1577_CR23","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1136\/gutjnl-2018-316408","volume":"68","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, Montal R, Bassaganyas L, Sia D, Takayama T, Chau GY, et al. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial. Gut . 2019;68:1065\u201375.","journal-title":"Gut"},{"key":"1577_CR24","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1097\/SLA.0b013e31821ad884","volume":"254","author":"KC Lim","year":"2011","unstructured":"Lim KC, Chow PK, Allen JC, Chia GS, Lim M, Cheow PC, et al. Microvascular invasion is a better predictor of tumor recurrence and overall survival following surgical resection for hepatocellular carcinoma compared to the Milan criteria. Ann Surg. 2011;254:108\u201313.","journal-title":"Ann Surg"},{"key":"1577_CR25","doi-asserted-by":"publisher","first-page":"215","DOI":"10.12659\/AOT.902595","volume":"22","author":"S Radunz","year":"2017","unstructured":"Radunz S, Treckmann J, Baba HA, Best J, M\u00fcller S, Theysohn JM, et al. Long-term outcome after liver transplantation for hepatocellular carcinoma following Yttrium-90 radioembolization bridging treatment. Ann Transplant. 2017;22:215\u201321.","journal-title":"Ann Transplant"},{"key":"1577_CR26","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1148\/radiol.2016151061","volume":"281","author":"M Okada","year":"2016","unstructured":"Okada M, Murakami T, Kuwatsuru R, Nakamura Y, Isoda H, Goshima S, et al. Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a Multicenter Study. Radiology. 2016;281:474\u201383.","journal-title":"Radiology"},{"key":"1577_CR27","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1016\/j.ejrad.2016.10.010","volume":"85","author":"Y Takatsu","year":"2016","unstructured":"Takatsu Y, Kobayashi S, Miyati T, Shiozaki T. Hepatobiliary phase images using gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI as an imaging surrogate for the albumin-bilirubin grading system. Eur J Radiol. 2016;85:2206\u201310.","journal-title":"Eur J Radiol"},{"key":"1577_CR28","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1097\/MEG.0000000000000772","volume":"29","author":"MN Braat","year":"2017","unstructured":"Braat MN, van Erpecum KJ, Zonnenberg BA, van den Bosch MA, Lam MG. Radioembolization-induced liver disease: a systematic review. Eur J Gastroenterol Hepatol. 2017;29:144\u201352.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1577_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s40644-019-0216-6","volume":"19","author":"S Gordic","year":"2019","unstructured":"Gordic S, Wagner M, Zanato R, Hectors S, Besa C, Kihira S, et al. Prediction of hepatocellular carcinoma response to (90)Yttrium radioembolization using volumetric ADC histogram quantification: preliminary results. Cancer Imaging. 2019;19:29.","journal-title":"Cancer Imaging"},{"key":"1577_CR30","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/jcm7040083","volume":"7","author":"A Niekamp","year":"2018","unstructured":"Niekamp A, Abdel-Wahab R, Kuban J, Odisio BC, Mahvash A, Hassan MM, et al. Baseline apparent diffusion coefficient as a predictor of response to liver-directed therapies in hepatocellular carcinoma. J Clin Med. 2018;7:83.","journal-title":"J Clin Med"},{"key":"1577_CR31","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1159\/000510798","volume":"9","author":"K Sch\u00fctte","year":"2020","unstructured":"Sch\u00fctte K, Schinner R, Fabritius MP, M\u00f6ller M, Kuhl C, Iezzi R, et al. Impact of extrahepatic metastases on overall survival in patients with advanced liver dominant hepatocellular carcinoma: a subanalysis of the SORAMIC Trial. Liver Cancer. 2020;9:771\u201386.","journal-title":"Liver Cancer"},{"key":"1577_CR32","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.2214\/AJR.12.8632","volume":"199","author":"S Siripongsakun","year":"2012","unstructured":"Siripongsakun S, Lee JK, Raman SS, Tong MJ, Sayre J, Lu DS. MRI detection of intratumoral fat in hepatocellular carcinoma: potential biomarker for a more favorable prognosis. Am J Roentgenol. 2012;199:1018\u201325.","journal-title":"Am J Roentgenol"},{"key":"1577_CR33","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3350\/cmh.2016.0088","volume":"23","author":"J An","year":"2017","unstructured":"An J, Lee KS, Kim KM, Park DH, Lee SS, Lee D, et al. Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion. Clin Mol Hepatol. 2017;23:160\u20139.","journal-title":"Clin Mol Hepatol"},{"key":"1577_CR34","doi-asserted-by":"publisher","first-page":"4219","DOI":"10.21873\/anticanres.13583","volume":"39","author":"SI Ariizumi","year":"2019","unstructured":"Ariizumi SI, Ban D, Abe Y, Kumamoto T, Koizumi S, Tanabe M, et al. High-signal-intensity MR image in the hepatobiliary phase predicts long-term survival in patients with hepatocellular carcinoma. Anticancer Res. 2019;39:4219\u201325.","journal-title":"Anticancer Res"},{"key":"1577_CR35","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"1577_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1200\/JCO.2021.39.3_suppl.295","volume":"39","author":"W Wang","year":"2021","unstructured":"Wang W, Wang J, Zhang X, Wang Y, Shi J, Jia X, et al. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma: a cost-effectiveness analysis. J Clin Oncol. 2021;39:295\u20135.","journal-title":"J Clin Oncol"},{"key":"1577_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-019-2079-9","volume":"17","author":"M Alunni-Fabbroni","year":"2019","unstructured":"Alunni-Fabbroni M, R\u00f6nsch K, Huber T, Cyran CC, Seidensticker M, Mayerle J, et al. Circulating DNA as prognostic biomarker in patients with advanced hepatocellular carcinoma: a translational exploratory study from the SORAMIC trial. J Transl Med. 2019;17:328.","journal-title":"J Transl Med"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01577-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01577-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01577-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,19]],"date-time":"2022-01-19T08:27:29Z","timestamp":1642580849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01577-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,22]]},"references-count":37,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2,1]]}},"alternative-id":["1577"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01577-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,22]]},"assertion":[{"value":"11 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 August 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study protocol was approved by the institutional review board of each participating centre and conducted in accordance with the Declaration of Helsinki. All patients gave written informed consent.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"BG: personal fees\u2014Bayer, Sirtex. IB: Grants\u2014Sirtex, during the conduct of the study. Personal fees\u2014Bayer, Sirtex, Biocompatibles, Terumo, outside the submitted work. MP: Grants\u2014Sirtex, Bayer; Personal fees\u2014Sirtex. PM: Grants\u2014Bayer, Sirtex. JR: Grants\u2014Sirtex, Bayer; Personal fees\u2014Sirtex, Bayer. MS: Personal fees\u2014Bayer, Sirtex.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}